scholarly journals Effects of antithrombin III (ATIII) treatment (high dose) in severe pre-eclampsia and HELLP syndrome with alterations of coagulation inhibitors and inflammatory markers: a preliminary report

Critical Care ◽  
10.1186/cc749 ◽  
2000 ◽  
Vol 4 (Suppl 1) ◽  
pp. P29 ◽  
Author(s):  
A Giarratano ◽  
G Cuccio ◽  
S Mangione
Keyword(s):  
Hellp Syndrome ◽  
Inflammatory Markers ◽  
Preliminary Report ◽  
Antithrombin Iii ◽  
High Dose ◽  
Coagulation Inhibitors

scholarly journals High-dose testosterone treatment reduces monoamine oxidase A levels in the human brain: a preliminary report

2021 ◽  
pp. 105381
Author(s):  
Georg S. Kranz ◽  
Marie Spies ◽  
Chrysoula Vraka ◽  
Ulrike Kaufmann ◽  
Eva-Maria Klebermass ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Human Brain ◽  
Preliminary Report ◽  
Monoamine Oxidase A ◽  
High Dose ◽  
Testosterone Treatment

scholarly journals Pulmonary function, computerized tomography features and six-minute walk test at three months in severe COVID-19 patients treated with intravenous pulsed methylprednisolone: a preliminary report

2021 ◽  
Author(s):  
Cristiano Van Zeller ◽  
Asad Anwar ◽  
Nordita Ramos-Bascon ◽  
Natalie Barnes ◽  
Brendan Madden
Keyword(s):  
Lung Function ◽  
Preliminary Report ◽  
Mean Value ◽  
High Dose ◽  
Walk Test ◽  
Six Minute Walk Test ◽  
High Dose Methylprednisolone ◽  
Randomised Controlled ◽  
Ct Finding ◽  
Minute Walk

COVID-19 ARDS has a high mortality and few therapeutic options. We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes. We performed a retrospective analysis of all patients treated with high-dose methylprednisolone for COVID-19 ARDS and three-month lung function, 6MWT, and CT findings. 15 patients were treated of which 10 survived to discharge. Reduced DLCO was the commonest abnormality in lung function tests and had the lowest mean value. Parenchymal bands were the commonest CT finding and 50% of patients had fibrosis at three-months. Mean 6MWD was 65.4% predicted and was abnormal in 62.5% of patients. In this cohort of patients with COVID-19 ARDS treated with high-dose methylprednisolone pulses, CT, lung function, and 6MWT abnormalities were unsurprisingly common at three months, although all 10 patients treated early in their disease course survived, a possible therapeutic effect. Further randomised controlled trials are needed to assess the benefits of this treatment.

scholarly journals Racial/ethnic Disparities on Inflammation and Response to Methylprednisolone in Severe Covid-19 Pneumonia

2021 ◽  
Author(s):  
Ronaldo C. Go ◽  
Themba Nyirenda ◽  
Maryam Bojarian ◽  
Davood Karimi Hosseini ◽  
Kevin Kim ◽  
...  
Keyword(s):  
Inflammatory Markers ◽  
Asian Indians ◽  
Low Dose ◽  
Ethnic Disparities ◽  
Prolonged Survival ◽  
High Dose ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
High Dose Methylprednisolone ◽  
Racial Ethnic

Abstract BACKGROUNDRacial/Ethnic minorities are at higher risk for Severe COVID-19. This may be related to social determinants that lead to chronic inflammatory states. The aims of the study were to determine if there are racial/ethnic differences between the inflammatory markers of survivors and non-survivors and if there was a dose dependent association of methylprednisolone to in hospital survival. METHODSThis was a secondary analysis of a retrospective cohort. Patients were older than 18 years of age and admitted for severe COVID-19 Pneumonia Between March to June 2020 in 13 Hospitals in New Jersey, United States. Comparison of inflammatory markers used Kruskal-Wallis followed by pairwise comparison using two-sided Wilcoxon rank sum test. A Youden Index Method was used to determine the cut-off between low dose and high dose methylprednisolone. For each racial/ethnic group, cox regression was used to determine the association to survival between no methylprednisolone and methylprednisolone (high dose versus low dose). RESULTSPropensity matched sample (n=759) between no methylprednisolone (n=380) and methylprednisolone (n=379) had 338 Whites, 102 Blacks, 61 Asian/Indians, and 251 Non-Black Non-White Hispanics. Interleukin-6, C-reactive protein, ferritin, and d-dimer values were higher in non-survivors compared to survivors except in Asian/Indian survivors who had higher ferritin values compared to non-survivors (median: 1,265 vs 418 ug/L, P=0.0211). Black and Hispanic survivors had persistently elevated C-reactive protein, (10.2 mg/mL) and (13.70 mg/mL) respectively. Low dose methylprednisolone was associated with prolonged 60 days in hospital survival over no methylprednisolone in Whites (P<0.0001), Asian/Indians (P=0.0180), and Hispanics (P=0.0004). Regardless of dose, methylprednisolone was not associated with prolonged survival in Blacks. High dose methylprednisolone was associated with worse survival in Hispanics. (P=0.0181). CONCLUSIONRacial/Ethnic disparities with inflammatory markers in survivors and non-survivors preclude the use of one marker as predictor of survival. Low dose methylprednisolone is associated with prolonged survival in Asian/Indians, Hispanics, and Whites. Methylprednisolone, regardless of dose, was not associated with prolonged survival in Blacks.

Plasma progesterone levels after using high dose suppositories. A preliminary report

1982 ◽  
Vol 4 (5) ◽  
pp. 135-136 ◽  
Author(s):  
Y. G. Van Der Meer ◽  
A. C. Van Loenen ◽  
E. W. Loendersloot ◽  
L. J. B. Jaszmann
Keyword(s):  
Preliminary Report ◽  
High Dose ◽  
Plasma Progesterone

Coagulation Inhibitors in Plasma and Serum

1975 ◽  
Author(s):  
O. R. Ødegård ◽  
U. Abildgaard
Keyword(s):  
Antithrombin Iii ◽  
Close Correlation ◽  
The Other ◽  
At Iii ◽  
Coagulation Inhibitors ◽  
Patient Groups ◽  
Cofactor Activity ◽  
The Difference ◽  
Immuno Assay ◽  
Activity Method

Heparin cofactor activity and antithrombin III (At-III) activity measured with amidolytic methods; antifactor Xa by a clotting method (Biggs et al., Brit. J. Haemat. 19, 287, 1970) and immunoassay of At-III (Fagerhol & Abildgaard, Scand. J. Haemat. 7, 10, 1970) in plasma and serum showed:1) There was a close correlation between the plasma values as measured by all these methods (r = 0.84–0.93).2) The difference between plasma and serum values (“consumption”) was lower in warfarin treated and in haemophiliacs than in the other groups.3) The difference between plasma and serum was greater when measured by the heparin cofactor activity method than by the other methods. The reason for this discrepancy will be discussed. The results in different patient groups will be reported.4) As the heparin cofactor activity assay can be completed within 10 minutes after blood sampling, and has a higher precision than clotting assay and immuno assay, it is preferable for clinical use.

scholarly journals Autoinflammatory constrictive pericarditis and chronic myelomonocytic leukaemia: when one speciality is not enough

2019 ◽  
Vol 12 (3) ◽  
pp. e228204
Author(s):  
Frances Varian ◽  
Harpreet Kaur ◽  
Stuart Carter ◽  
Julian Gunn
Keyword(s):  
Bone Marrow ◽  
Surgical Treatment ◽  
Cardiac Function ◽  
Constrictive Pericarditis ◽  
Inflammatory Markers ◽  
Multiorgan Failure ◽  
Intravenous Immunoglobulins ◽  
Sustained Response ◽  
High Dose ◽  
Chronic Myelomonocytic Leukaemia

We present a case of constrictive pericarditis with concomitant blood and bone marrow appearances of chronic myelomonocytic leukaemia (CMML). Despite surgical treatment with pericardiectomy, the patient deteriorated into multiorgan failure. Pericardial histology disclosed a typical inflammatory picture with no evidence of monocytic or malignant infiltrate. Following intensive collaboration between cardiologists, haematologists and rheumatologists via daily email exchanges, a diagnosis was reached of autoinflammatory constrictive pericarditis with a non-infiltrative coexisting CMML. The key to achieving a rapid and sustained response was a trial of high-dose steroids followed by intravenous immunoglobulins. This achieved restoration of cardiac function, resolution of symptoms and near normalisation of inflammatory markers. A diagnosis of concurrent CMML was confirmed at 3 months. The patient remains well, taking colchicine and steroids.

scholarly journals Preeclampsia, HELLP Syndrome, and Postpartum Renal Failure with Thin Basement Membrane Nephropathy: Case Report and a Brief Review of Postpartum Renal Failure

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
K. C. Janga ◽  
Pavani Chitamanni ◽  
Shraddha Raghavan ◽  
Kamlesh Kumar ◽  
Sheldon Greenberg ◽  
...  
Keyword(s):  
Renal Failure ◽  
Basement Membrane ◽  
Renal Biopsy ◽  
Hellp Syndrome ◽  
Tubulointerstitial Nephritis ◽  
Laboratory Evaluation ◽  
High Dose ◽  
Acute Tubulointerstitial Nephritis ◽  
Thin Basement Membrane Nephropathy ◽  
First Case

A 36-year-old primigravida female from a birthing center was referred for elevated blood pressure to the hospital two days after normal spontaneous vaginal delivery with nausea, vomiting, and diarrhea. During this two-day period, she was experiencing persistent vaginal bleeding and lower abdominal pains for which she took six doses of 600 mg ibuprofen. Further laboratory evaluation reflected leukocytosis, anemia, thrombocytopenia, elevation of liver enzymes, and renal failure with hyperkalemia requiring emergent hemodialysis once in the Medical Intensive Care Unit (MICU). She was diagnosed with HELLP syndrome with underlying preeclampsia. A week later, due to hypertension controlled with medications and nonoliguric renal failure with no active urine sediments, a renal biopsy was indicated to direct management. The renal biopsy supported the diagnosis of diffuse severe acute tubulointerstitial nephritis with hypereosinophilia and thin basement membrane nephropathy (see figures). She was subsequently treated with high-dose steroids which resulted in the normalization of blood pressures and renal function returning to baseline. We report the first case of acute tubulointerstitial nephritis in an individual with thin basement membrane nephropathy secondary to postpartum complications.

P826Peri-procedural treatment with high dose Rosuvastatin reduces soluble TNF receptor 1 in patients treated with primary percutaneous coronary intervention for ST elevation myocardial infarction

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A I Larsen ◽  
N Butt ◽  
P Aukrust ◽  
P S Munk ◽  
J M Nilsen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Primary Percutaneous Coronary Intervention ◽  
Inflammatory Markers ◽  
Coronary Intervention ◽  
High Dose ◽  
Tnf Receptor ◽  
Percutaneous Coronary ◽  
St Elevation ◽  
Soluble Tnf Receptor

Abstract Background The extent of cardiac injury in ST elevation myocardial infarction (STEMI) depends on the level of inflammation and subsequent immune cell recruitment. An inflammatory phase that is disproportionately prolonged, of excessive magnitude, or insufficiently suppressed, can lead to sustained tissue damage and improper healing, promoting infarct expansion, adverse remodelling and chamber dilatation. Soluble TNF receptor 1 (sTNFR-1) is believed to mirror systemic pan-inflammatory status more closely than a single cytokine antigenic level. sTNFR-1 levels might give prognostic information, independent from and, at the same time, additive with some well-recognized outcome predictors such as left ventricular ejection fraction. Purpose We hypothesised that sTNFR-1 and other inflammatory markers could be modulated by statins. Methods Plasma levels of inflammatory markers were measured at baseline, 2 days, 7 days and 2 months in consecutive patients with first time STEMI with single vessel disease. Twenty-five patients (treatment group (TG)) were treated with 80 mg Rosuvastatin daily with first dose before primary percutaneous coronary intervention (PCI) whereas the control group (CG) consisted of 34 patients in whom treatment with 20 mg simvastatin daily were initiated the day after PPCI. Results sTNFR1 increased during the first 48 hours following PCI and this increase was larger in the CG compared with the TG (0.22±0.30 ng/mL vs 0.08±0.19 ng/nmL, p=0.025). The difference in increase during one week was only borderline statistically significant (0.21±0.30 ng/mL vs 0.08±0.26 ng/mL, p=0.081). These differences in the kinetics of sTNRF-1 were mirrored by changes in Pentraxin 3 (PTX3) between groups from baseline to 1 week, CG vs TG. (0.28±0.70 μmol/l vs 0.10±0.05 ng/mL, p=0.014) and at 2 months (−0.42±0.56 ng/mL vs 0.08±0.60 μmol/l, p=0.032) Conclusion High dose Rosuvastatin therapy initiated peri-procedural during PPCI for STEMI reduces pan inflammation as reflected by sTNFR1 and is associated with a less abrupt fall in PTX3 at 1 week and 2 months supporting recent research suggesting that PTX3 plays a cardiovascular protective effect in cardiovascular disease and healing. Acknowledgement/Funding Western Norway Regional Health Authority

Sign in / Sign up

Export Citation Format

Share Document